Truvestments Capital’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-11
Closed -$3K 975
2022
Q3
$3K Hold
11
﹤0.01% 537
2022
Q2
$3K Buy
+11
New +$2.97K ﹤0.01% 546
2022
Q1
Sell
-11
Closed -$4K 605
2021
Q4
$4K Hold
11
﹤0.01% 519
2021
Q3
$4K Hold
11
﹤0.01% 492
2021
Q2
$3K Hold
11
﹤0.01% 534
2021
Q1
$4K Hold
11
﹤0.01% 556
2020
Q4
$3K Buy
+11
New +$3.04K ﹤0.01% 538
2020
Q3
Sell
-34
Closed -$8K 592
2020
Q2
$8K Buy
34
+32
+1,600% +$6.42K 0.01% 410
2020
Q1
$0 Buy
+2
New +$332 ﹤0.01% 562
2019
Q4
Sell
-41
Closed -$7K 650
2019
Q3
$7K Sell
41
-5
-11% -$1.08K ﹤0.01% 544
2019
Q2
$12K Hold
46
0.01% 512
2019
Q1
$13K Buy
+46
New +$15.3K 0.01% 482
2018
Q3
$19K Buy
+43
New +$17K 0.01% 525

Other funds holding ABMD

Truvestments Capital's ABMD Position: Q4 2022 in Review

Truvestments Capital sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 11 shares — an estimated $3K sold.

Truvestments Capital first reported a position in ABMD in Q3 2018 and held it in 13 quarters. The position peaked at $19K in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Truvestments Capital reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Truvestments Capital sold 11 Abiomed Inc shares in Q4 2022, an estimated $3K.
  • Truvestments Capital first reported a position in Abiomed Inc in Q3 2018 and held it in 13 quarters.
  • Truvestments Capital's Abiomed Inc position peaked at $19K in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Truvestments Capital's 13F filing for Q4 2022, filed 14 Feb 2023.